Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
‘Aid for Ukraine’ pierogi fundraiser event - 2Kaiser Permanente affiliates to pay $556 million to resolve US claims alleging Medicare fraud
- 3Examination In progress into Abuse of Japanese Government-Supported Advance
- 4Six Flags Opens the Tallest, Fastest and Longest Roller Coaster in the World
- 5Instructions to Construct an Organization While Chasing after a Web-based Degree
- Mossad unveils network of Hamas terror infrastructure across Europe
- Fireball sightings are surging across the US — here's what's really going on
- Figure out How to Use Your Nursing Abilities for Better Compensation
- This Miraculous, Cliff-Perched Town In The South Of France Is A Sacred European Gem
- Upgrading the Healthy benefit of Your Local Vegetables
- Major railway disruptions persist as Germany braces for more snow
- The Best Portable Applications for Emotional wellness and Prosperity
- Instructions to Really Oversee Unsold SUVs in the Auto Business
- Scientists discover black hole flare with the light of 10 trillion suns
